Affordable Insulin Now Act of 2026
SB4512, the Affordable Insulin Now Act of 2026, would cap out-of-pocket costs for certain insulin products covered by private health plans and create a federal reimbursement program for insulin furnished to uninsured individuals. For plan years beginning on or after January 1, 2027, group health plans and health insurance issuers offering group or individual coverage would have to cover at least one selected insulin product in each dosage form and type, prohibit deductibles for those products, and limit cost-sharing to the lesser of $35 per 30-day supply or 25 percent of the negotiated price net of price concessions. The bill applies these requirements across the major federal health coverage frameworks, including the Public Health Service Act, ERISA, and the Internal Revenue Code, and it specifies that the insulin cost-sharing counts toward deductibles and out-of-pocket maximums.
The bill also directs the Secretary of Health and Human Services to establish a program to reimburse qualifying pharmacies and health care providers that furnish insulin to uninsured individuals. Under that program, the federal government would pay the difference between the uninsured person’s out-of-pocket cost and $35 for each 30-day supply, provided the provider or pharmacy agrees not to bill the individual for the covered amount and meets any additional standards set by HHS. The bill further states that Congress should later enact an offset for any federal costs associated with the measure.
If enacted, SB4512 would amend federal health insurance law to impose a nationwide insulin cost-sharing ceiling for private coverage, including employer-sponsored plans, individual market plans, and catastrophic plans, while preserving higher cost-sharing for out-of-network insulin and leaving non-selected insulin products subject to existing law. It would also modify the Affordable Care Act’s actuarial value rules so the insulin deductible exemption would not reduce the calculated value of qualified health plans. In addition, it would create a new federal payment mechanism for insulin provided to uninsured people, affecting pharmacies, health care providers, insurers, and plan sponsors by shifting some insulin costs away from patients and onto plans or the federal government.
The available context suggests generally favorable intent around lowering insulin costs and improving access, but there is no recorded committee debate or vote history in the materials provided. The bill’s structure, including a $35 cap and a reimbursement program for uninsured individuals, indicates a consumer-protection and affordability focus. The inclusion of a sense-of-Congress statement calling for a future offset suggests some awareness of budgetary concerns even though no formal opposition is documented here.
The main points of potential contention are likely to be cost and scope. Insurers, employers, and pharmacy benefit managers may object to the mandated cost-sharing limits and the requirement to count those payments toward deductibles and out-of-pocket maximums, while policymakers concerned about federal spending may focus on the new reimbursement program for uninsured individuals and the bill’s lack of an immediate offset. There may also be debate over the bill’s reliance on selected insulin products, the treatment of out-of-network services, and the extent to which federal requirements should preempt or interact with existing state insurance rules.